23 October 2024 - NICE has published final evidence-based recommendations on the use of quizartinib dihydrochloride (Vanflyta) for the induction, consolidation and maintenance treatment of adults with newly diagnosed FLT3-ITD positive acute myeloid leukaemia.

Quizartinib dihydrochloride is recommended as an option for the treatment of adults with newly diagnosed FLT3‑ITD positive acute myeloid leukaemia when used with standard cytosine arabinoside and anthracycline chemotherapy as induction treatment, then with standard cytosine arabinoside chemotherapy as consolidation treatment and then alone as maintenance treatment.

Quizartinib dihydrochloride is only recommended if Daiichi Sankyo provides it according to the commercial arrangement.

Read NICE technology appraisal guidance